Assessment of excess medical costs for persons with type 2 diabetes according to age groups: an analysis of German health insurance claims data.
Journal
Diabetic medicine : a journal of the British Diabetic Association
ISSN: 1464-5491
Titre abrégé: Diabet Med
Pays: England
ID NLM: 8500858
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
accepted:
10
12
2019
pubmed:
14
12
2019
medline:
3
11
2021
entrez:
14
12
2019
Statut:
ppublish
Résumé
This cross-sectional study used a large nationwide claims data set to assess the excess medical costs of people with type 2 diabetes according to age group in 2015. Data from 291 709 people with diabetes and 291 709 age- and sex-matched controls were analysed. Total costs (expressed as 2015 euros) of outpatient and inpatient services, medication, rehabilitation, and the provision of aids and appliances were examined. Overall and age-stratified excess costs of people with diabetes were estimated using gamma regression with a log-link. Overall, the estimated total direct costs of a person with type 2 diabetes are approximately double those of a person without diabetes: €4727 vs. €2196, respectively. Absolute excess costs were approximately the same in all age groups (around €2500), however, relative excess costs of persons with diabetes were much higher in younger (~ 334% for < 50 years) than in older age groups (~ 156% for ≥ 80 years). Regional costs, both absolute and excess, partly differed from the national level. This study complements and updates previous studies on the excess medical costs of people with diabetes in Germany. The results indicate the importance of preventing the development of type 2 diabetes, especially in younger age groups. Longitudinal and regional studies examining changes in prevalence and the development of excess costs in groups with different types of diabetes, and according to age, would be of interest to validate our findings and better understand the avoidable burden of having diabetes.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1752-1758Subventions
Organisme : Bavarian State Ministry of Food, Agriculture and Forestry
Pays : International
Informations de copyright
© 2019 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK.
Références
Heidemann C, Scheidt-Nave C. Prevalence, incidence and mortality of diabetes mellitus in adults in Germany - a review in the framework of the diabetes surveillance. J Health Monit 2017; 2: 98-121.
Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus-present and future perspectives. Nat Rev Endocrinol 2011; 8: 228-236.
Gregg EW. The changing tides of the type 2 diabetes epidemic-smooth sailing or troubled waters ahead? Kelly West Award Lecture 2016. Diabetes Care 2017; 40: 1289-1297.
Bommer C, Sagalova V, Heesemann E, Manne-Goehler J, Atun R, Barnighausen T et al. Global economic burden of diabetes in adults: projections from 2015 to 2030. Diabetes Care 2018; 41: 963-970.
Yoon U, Kwok LL, Magkidis A. Efficacy of lifestyle interventions in reducing diabetes incidence in patients with impaired glucose tolerance: a systematic review of randomized controlled trials. Metabolism 2013; 62: 303-314.
Matte ME, Velonakis EG. Type 2 diabetes prevention programs; how far are we? J Diabetes Metab 2015; 5: 460.
Laxy M, Knoll G, Schunk M, Meisinger C, Huth C, Holle R. Quality of diabetes care in Germany improved from 2000 to 2007 to 2014, but improvements diminished since 2007. evidence from the population-based KORA studies. PloS One 2016; 11: e0164704.
Laxy M, Stark R, Meisinger C, Kirchberger I, Heier M, von Scheidt W et al. The effectiveness of German disease management programs (DMPs) in patients with type 2 diabetes mellitus and coronary heart disease: results from an observational longitudinal study. Diabetol Metab Syndr 2015; 7: 77.
Köster I, Huppertz E, Hauner H, Schubert I. Costs of diabetes mellitus (CoDiM) in Germany, direct per-capita costs of managing hyperglycaemia and diabetes complications in 2010 compared to 2001. Exp Clin Endocrinol Diabetes 2014; 122: 510-516.
Köster I, Schubert I, Huppertz E. [Follow up of the CoDiM study: cost of diabetes mellitus 2000-2009]. Deutsche Med Wochenschr 2012; 137: 1013-1016.
von Ferber L, Koster I, Hauner H. Medical costs of diabetic complications total costs and excess costs by age and type of treatment results of the German CoDiM Study. Exp Clin Endocrinol Diabetes 2007; 115: 97-104.
Hoffmann F, Icks A. Diabetes ‘epidemic’ in Germany? A critical look at health insurance data sources. Exp Clin Endocrinol Diabetes 2012; 120: 410-415.
Federal Statistical Office. Information System of Federal Health Monitoring. Available at www.gbe-bund.de Last accessed 27 June 2019.
Pollmanns J, Weyermann M, Geraedts M, Drosler SE. [Hospitalizations and amputations for diabetes mellitus-trends and small-area variation in Germany]. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2018; 61: 1462-1471.
Swart E, Gothe H, Geyer S, Jaunzeme J, Maier B, Grobe TG et al. [Good practice of secondary data analysis (GPS): guidelines and recommendations]. Gesundheitswesen 2015; 77: 120-126.
Kähm K, Laxy M, Schneider U, Rogowski WH, Lhachimi SK, Holle R. Health care costs associated with incident complications in patients with type 2 diabetes in Germany. Diabetes Care 2018; 41: 971-978.
Kähm K, Laxy M, Schneider U, Holle R. Exploring different strategies of assessing the economic impact of multiple diabetes-associated complications and their interactions: a large claims-based study in Germany. PharmacoEconomics 2019; 37: 63-74.
Ulrich S, Holle R, Wacker M, Stark R, Icks A, Thorand B et al. Cost burden of type 2 diabetes in Germany: results from the population-based KORA studies. BMJ Open 2016; 6: e012527.
Buntin MB, Zaslavsky AM. Too much ado about two-part models and transformation? Comparing methods of modeling Medicare expenditures. J Health Econ 2004; 23: 525-542.
Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care 2012; 18: 721-726.
Muller N, Heller T, Freitag MH, Gerste B, Haupt CM, Wolf G et al. Healthcare utilization of people with type 2 diabetes in Germany: an analysis based on health insurance data. Diabet Med 2015; 32: 951-957.
Jacobs E, Hoyer A, Brinks R, Icks A, Kuss O, Rathmann W. Healthcare costs of type 2 diabetes in Germany. Diabet Med 2017; 34: 855-861.
Hoffmann F, Icks A. Diabetes prevalence based on health insurance claims: large differences between companies. Diabet Med 2011; 28: 919-923.
Federal Statistical Office: Health Expenditure. Available at https://www.destatis.de/EN/Themes/Society-Environment/Health/Health-Expenditure/Tables/sources-of-funding.html Last accessed 27 September 2019.
American Diabetes Association. Economic Costs of Diabetes in the U.S. in 2017. Diabetes Care 2018; 41: 917-928.
Zhuo X, Zhang P, Barker L, Albright A, Thompson TJ, Gregg E. The lifetime cost of diabetes and its implications for diabetes prevention. Diabetes Care 2014; 37: 2557-2564.
Shrestha SS, Zhang P, Hora IA, Gregg EW. Trajectory of excess medical expenditures 10 years before and after diabetes diagnosis among U.S. adults aged 25-64 years, 2001-2013. Diabetes Care 2019; 42: 62-68.
Hallberg SJ, McKenzie AL, Williams PT, Bhanpuri NH, Peters AL, Campbell WW et al. Effectiveness and safety of a novel care model for the management of type 2 diabetes at 1 year: an open-label, non-randomized, controlled study. Diabetes Ther 2018; 9: 583-612.
Lean ME, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet 2018; 391: 541-551.
White M. Population approaches to prevention of type 2 diabetes. PLoS Med 2016; 13: e1002080.